Funded Local Who is raising money in your own backyard?

Financing to Advance Commercialization of Expanded Portfolio of Vascular Products

BDC Venture Capital and GrowthWorks Capital confirm commitment to multiple award-winning 'office-in-a-box' solution

June 3, 2008, Vancouver, B.C.- Sutus Inc., the company behind the Sutus Business Central™, a unique all-in-one device that combines all IT data communications and Telephony features required to run a modern-day office, today announced it has secured $5 million in funding from BDC Venture Capital and GrowthWorks Capital. The funding will be used for sales and channel expansion as the company continues to grow since launching its flagship product in late 2007.

March 14, 2008 - enGene Inc., a privately held biotechnology company developing an innovative approach for the treatment of diabetes called GEMSTM-Insulin, announced today it has raised US$6.4 million in a Series A financing, consisting of new investment and conversion of an existing convertible note financing. The financing was led by Saad Investments Company Ltd. and included Masa Life Science Ventures LP (MLSV) of Washington, DC and private investors.

March 14, 2008 - Officials from the Government of Canada, EnCana Corporation (TSX, NYSE: ECA) and Sustainable Development Technology Canada (SDTC) announced today they are committing $5.5 million in financing to a NxtGen Emission Controls project which demonstrates an innovative diesel emission reduction system. NxtGen’s syngas technology will assist diesel trucks in complying with stringent global emission reduction regulations and has the potential to enable manufacturers to increase fuel economy.

Vancouver, Canada – December 10, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP; the “Company”), a medical technology company developing photodisinfection based products, today announced that it has closed upon its previously announced private placement pursuant to which the Company has now increased its private placement to be comprised of the issuance of an aggregate of 6,335,182 units (instead of the previously announced 5,000,000) of the Company, at a subscription price of $1.10 per unit, for gross proceeds of approximately C$7.0 million (that being an aggregate of approxima

Vancouver, British Columbia, November 20, 2007 – Protox Therapeutics Inc. (TSX-V: PRX), a leader in advancing, targeted toxin therapeutics for the treatment of cancer and other proliferative diseases, announced today that it has received approximately $7.6 million of a potential $7.7 million from the exercise of warrants issued as a result of the two tranches of a unit private placement financing closed on November 4 and 17, 2005. Any remaining warrants relating to this financing have now expired. This brings the current cash position of the Company to just over $12 million.

wavefront(tm) to Provide Services to Catalyze Wireless Developer Marketplace
The government of the province of British Columbia has shown its strong support of the wireless industry in BC through its recent funding of wavefront. The Ministry of Advanced Education has provided $5 million in funding to help wavefront with startup and operational costs. wavefront will provide testing and commercialization services to the wireless developer community.

Vancouver, British Columbia, October 26, 2007 – Protox Therapeutics Inc. (TSX-V:PRX), a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases, announced today that it has already received a total of approximately $5.2 million of a potential $7.7 million from the exercise of warrants issued as a result of the two tranches of a private placement financing dated November 4 and 17, 2005. This brings the approximate current cash position of the Company to just over $10.0 million.

VANCOUVER, B.C. July 30, 2007 - MetroBridge Networks International Inc., a premier high-speed wireless broadband provider for business in British Columbia with operations in Arizona, is pleased to announce that it has successfully completed the reverse take over of Huntingdon Capital Inc.

Vancouver, BC, May 28, 2007--(T-Net)--The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine their discoveries and develop them for commercial use, received an additional $8 million in funding for its core facility. This investment matches the $8 million Canada Foundation for Innovation (CFI) grant CDRD received last November. It also comes on the heels of a $25 million funding grant from the Province of BC announced last month by Premier Gordon Campbell at the 2007 British Columbia Life Sciences Awards.